Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Promising Safety and Efficacy of Trovocabtagene Autoleucel (C-CAR088) Followed ASCT in Ultra High-Risk Multiple Myeloma (UHR-MM) Patients

Blood (2024) 144 (Supplement 1): 7236.

https://doi.org/10.1182/blood-2024-197883

Published: 2024

Journal Articles

Evaluation of D-Vrd Induction/Consolidation Therapy with MRD-Adapted Maintenance in Transplant-Eligible NDMM Patients with Double-Hit Cytogenetic Abnormality (MMY2094)

Chenxing Du, Shuaishuai Zhang, Lugui Qiu, Gang An, Wenqiang Yan, Jian Cui, Weiwei Sui, Shuhui Deng, Yan Xu, Shuhua Yi, Dehui Zou

Blood (2024) 144 (Supplement 1): 7068.

https://doi.org/10.1182/blood-2024-207775

Published: 2024

Journal Articles

Analysis of Diagnosis and Treatment Pattern for Newly Diagnosed Multiple Myeloma in China over 20 Years

Jingyu Xu, Yuntong Liu, Wenqiang Yan, Lingna Li, Rui Lyu, Chenxing DU, Weiwei Sui, Lugui Qiu, Gang An

Blood (2024) 144 (Supplement 1): 6917.

https://doi.org/10.1182/blood-2024-201167

Published: 2024

Journal Articles

Clinical Implications of Residual Immunophenotypically Normal Plasma Cells within Bone Marrow at Various Disease Stages in Multiple Myeloma

Wenqiang Yan, Lihui Shi, Jingyu Xu, Lingna Li, Jian Cui, Chenxing DU, Tengteng Yu, Shuaishuai Zhang, Rui Lv, Weiwei Sui, Shuhui Deng, Yan Xu, Dehui Zou, Lu-Gui Qiu, Mu Hao, Gang An

Blood (2024) 144 (Supplement 1): 1932.

https://doi.org/10.1182/blood-2024-199452

Published: 2024

Journal Articles

CAC-MM-001: A B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T-Cell (CAR-T) Therapy Followed By Autologous Stem Cell Transplantation and Second CAR-T (CART-ASCT-CART2) in Newly Diagnosed Multiple Myeloma Patients with P53 Gene Abnormalities

Yuntong Liu, Weiwei Sui, Rui Lyu, Chenxing DU, Shuaishuai Zhang, Tengteng Yu, Jingyu Xu, Wenqiang Yan, Yuting Yan, Wei Liu, Yi Wang, Qi Wang, Yan Xu, Shuhua Yi, Dehui Zou, Lu-Gui Qiu, Gang An

Blood (2024) 144 (Supplement 1): 3386.

https://doi.org/10.1182/blood-2024-200117

Published: 2024

Journal Articles

BCMA CAR-T Therapy As First-Line Consolidation Treatment in Transplant-Ineligible Patients with Newly-Diagnosed Multiple Myeloma: An Open Label, Single-Arm, Phase 2 Study (CAREMM-001)

Wenqiang Yan, Chenxing DU, Rui Lv, Tengteng Yu, Shuaishuai Zhang, Tingyu Wang, Weiwei Sui, Shuhui Deng, Yan Xu, Shuhua Yi, Dehui Zou, Lu-Gui Qiu, Gang An

Blood (2024) 144 (Supplement 1): 3385.

https://doi.org/10.1182/blood-2024-199913

Published: 2024

Journal Articles

A Phase 2 Study of CART-ASCT-CART2 Sandwich Regimen Treatment in Patients with Primary Plasma Cell Leukemia

Jingyu Xu, Shuaishuai Zhang, Wenqiang Yan, Yuntong Liu, Rui Lyu, Chenxing DU, Weiwei Sui, Lu-Gui Qiu, Gang An

Blood (2024) 144 (Supplement 1): 3389.

https://doi.org/10.1182/blood-2024-200847

Published: 2024

Journal Articles

Promising Safety and Efficacy of Trovocabtagene Autoleucel (C-CAR088) Followed ASCT in Ultra High-Risk Multiple Myeloma (UHR-MM) Patients Who Failed or Had Suboptimal Response to Standard First Line Triplet Based Therapy

Blood (2023) 142 (Supplement 1): 6864.

https://doi.org/10.1182/blood-2023-184868

Published: 2023

Journal Articles

Mitoxantrone Hydrochloride Liposome, Gemcitabine, Vinorelbine with or without Rituximab (GVM±R) in Patients with Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

Wei Liu, Yi Wang, Yan Xu, Chenxing Du, Qi Wang, Tingyu Wang, Wenyang Huang, Shuaishuai Zhang, Shuhua Yi, Yuting Yan, Tengteng Yu, Weiwei Sui, Gang An, Rui Lyu, Huimin Liu, Wenjie Xiong, Mingwei Fu, Dehui Zou, Lugui Qiu

Blood (2023) 142 (Supplement 1): 6232.

https://doi.org/10.1182/blood-2023-185669

Published: 2023

Journal Articles

The Specific Transcriptional Signature and Clonal Selection of MGUS-like Profile Predict an Exceptionally Favorable Prognosis in Patients with Newly-Diagnosed Multiple Myeloma

Wenqiang Yan, Chen Qiu, Chenxing Du, Shuhui Deng, Weiwei Sui, Yan Xu, Dehui Zou, Weiping Yuan, Lugui Qiu, Gang An

Blood (2023) 142 (Supplement 1): 879.

https://doi.org/10.1182/blood-2023-180351

Published: 2023

Journal Articles

Hyposecretory Progression Pattern Indicates Inferior Survival of Multiple Myeloma

Jingyu Xu, Wenqiang Yan, Lingna Li, Chenxing Du, Lugui Qiu, Gang An

Blood (2023) 142 (Supplement 1): 1955.

https://doi.org/10.1182/blood-2023-178217

Published: 2023

Journal Articles

Impact of Neoplastic Plasma Cells in the Stem Cell Collection on Multiple Myeloma Patients Receiving Autologous Stem Cell Transplantation

Jingyu Xu, Lingna Li, Wenqiang Yan, Huishou Fan, Jiahui Liu, Chenxing Du, Shuhui Deng, Weiwei Sui, Yan Xu, Lugui Qiu, Gang An

Blood (2022) 140 (Supplement 1): 10011–10012.

https://doi.org/10.1182/blood-2022-165889

Published: 2022

Journal Articles

Long-Term Activity of Combining CNCT19 with HDT/ASCT in Refractory Large B-Cell Lymphoma: Two-Year Follow-up of a Prospective Phase 1/2 Clinical Trial

Wei Liu, Hesong Zou, Yan Xu, Huimin Liu, Chenxing Du, Rui Lv, Wenyang Huang, Weiwei Sui, Shuhua Yi, Lulu Lv, Lugui Qiu, Jianxiang Wang, Dehui Zou

Blood (2022) 140 (Supplement 1): 7472–7473.

https://doi.org/10.1182/blood-2022-166451

Published: 2022

Journal Articles

The Impact of Dynamic Assessment of Risk Stratification at the Time of Disease Progression in Patients with Multiple Myeloma

Huishou Fan, Wenqiang Yan, Jingyu Xu, Chenxing Du, Weiwei Sui, Shuhui Deng, Dehui Zou, Lugui Qiu, Gang An

Blood (2022) 140 (Supplement 1): 4371–4373.

https://doi.org/10.1182/blood-2022-157223

Published: 2022

Journal Articles

Real-World Retrospective Study of 46 Patients with Macrofocal Multiple Myeloma (MFMM)

Wenqiang Yan, Huishou Fan, Jingyu Xu, Jiahui Liu, Chenxing Du, Shuhui Deng, Weiwei Sui, Yan Xu, Lugui Qiu, Gang An

Blood (2021) 138 (Supplement 1): 3765.

https://doi.org/10.1182/blood-2021-149464

Published: 2021

Journal Articles

Prognostic Impact of Hyperdiploidy on Multiple Myeloma in the Era of New Agents

Yi Wang, Jing Zhuang, Gang An, MD PhD, Xue-Han Mao, MD, Chenxing Du, MD, Jiahui Liu, Huishou Fan, Shuhui Deng, MD, Yan Xu, MD, Weiwei Sui, Lugui Qiu, MD

Blood (2020) 136 (Supplement 1): 20.

https://doi.org/10.1182/blood-2020-141188

Published: 2020

Journal Articles

The Prognostic Impact of Dynamic Changes of Genetic Risk Stratification in Multiple Myeloma

Blood (2020) 136 (Supplement 1): 1–3.

https://doi.org/10.1182/blood-2020-139345

Published: 2020

Journal Articles

Novel Insight into Multi-Hit Multiple Myeloma Based on "Two-Hit" Theory of Cancer Causation

Chenxing Du, MD, Xue-Han Mao, MD, Jiahui Liu, Huishou Fan, Weiwei Sui, MD, Shuhui Deng, MD, Shuhua Yi, MD, Wenyang Huang, Yan Xu, Chengwen Li, Jiawei Zhao, Dehui Zou, MD, Yaozhong Zhao, Jianxiang Wang, MD, Lugui Qiu, MD, Gang An, MD PhD

Blood (2020) 136 (Supplement 1): 47–48.

https://doi.org/10.1182/blood-2020-140909

Published: 2020

Journal Articles

The Relative Risk of Prognostic Factors of Age Stratified Multiple Myeloma

Chenxing Du, MD, Yi Wang, Xue-Han Mao, MD, Yuting Yan, Jiahui Liu, Huishou Fan, Yan Xu, Weiwei Sui, MD, Shuhui Deng, MD, Fu Mingwei, MD, Chengwen Li, Jiawei Zhao, Shuhua Yi, MD, Dehui Zou, MD, Yaozhong Zhao, Lugui Qiu, MD, Gang An, MD PhD

Blood (2020) 136 (Supplement 1): 26–27.

https://doi.org/10.1182/blood-2020-140718

Published: 2020

Journal Articles

Multiple Myeloma Cell Defects Erythropoiesis and Results Anemia Via High Level of CCL3 in Bone Marrow Microenvironment

Lanting Liu, Zhen Yu, MD, Hui Cheng, Weiwei Sui, Shuhui Deng, MD, Xiaojing Wei, Chenxing Du, MD, Wenyang Huang, Gang An, Wen Zhou, PhD, Tao Cheng, Lugui Qiu, MD, Mu Hao

Blood (2020) 136 (Supplement 1): 55.

https://doi.org/10.1182/blood-2020-139006

Published: 2020

NARROW

Promising Safety and Efficacy of Trovocabtagene Autoleucel (C-CAR088) Followed ASCT in Ultra High-Risk Multiple Myeloma (UHR-MM) Patients

Evaluation of D-Vrd Induction/Consolidation Therapy with MRD-Adapted Maintenance in Transplant-Eligible NDMM Patients with Double-Hit Cytogenetic Abnormality (MMY2094)

Analysis of Diagnosis and Treatment Pattern for Newly Diagnosed Multiple Myeloma in China over 20 Years

Clinical Implications of Residual Immunophenotypically Normal Plasma Cells within Bone Marrow at Various Disease Stages in Multiple Myeloma

CAC-MM-001: A B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T-Cell (CAR-T) Therapy Followed By Autologous Stem Cell Transplantation and Second CAR-T (CART-ASCT-CART2) in Newly Diagnosed Multiple Myeloma Patients with P53 Gene Abnormalities

BCMA CAR-T Therapy As First-Line Consolidation Treatment in Transplant-Ineligible Patients with Newly-Diagnosed Multiple Myeloma: An Open Label, Single-Arm, Phase 2 Study (CAREMM-001)

A Phase 2 Study of CART-ASCT-CART2 Sandwich Regimen Treatment in Patients with Primary Plasma Cell Leukemia

Promising Safety and Efficacy of Trovocabtagene Autoleucel (C-CAR088) Followed ASCT in Ultra High-Risk Multiple Myeloma (UHR-MM) Patients Who Failed or Had Suboptimal Response to Standard First Line Triplet Based Therapy

Mitoxantrone Hydrochloride Liposome, Gemcitabine, Vinorelbine with or without Rituximab (GVM±R) in Patients with Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

The Specific Transcriptional Signature and Clonal Selection of MGUS-like Profile Predict an Exceptionally Favorable Prognosis in Patients with Newly-Diagnosed Multiple Myeloma

Hyposecretory Progression Pattern Indicates Inferior Survival of Multiple Myeloma

Impact of Neoplastic Plasma Cells in the Stem Cell Collection on Multiple Myeloma Patients Receiving Autologous Stem Cell Transplantation

Long-Term Activity of Combining CNCT19 with HDT/ASCT in Refractory Large B-Cell Lymphoma: Two-Year Follow-up of a Prospective Phase 1/2 Clinical Trial

The Impact of Dynamic Assessment of Risk Stratification at the Time of Disease Progression in Patients with Multiple Myeloma

Real-World Retrospective Study of 46 Patients with Macrofocal Multiple Myeloma (MFMM)

Prognostic Impact of Hyperdiploidy on Multiple Myeloma in the Era of New Agents

The Prognostic Impact of Dynamic Changes of Genetic Risk Stratification in Multiple Myeloma

Novel Insight into Multi-Hit Multiple Myeloma Based on "Two-Hit" Theory of Cancer Causation

The Relative Risk of Prognostic Factors of Age Stratified Multiple Myeloma

Multiple Myeloma Cell Defects Erythropoiesis and Results Anemia Via High Level of CCL3 in Bone Marrow Microenvironment

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only